Equillium announces multiple abstracts accepted for presentation at acr convergence 2021

La jolla, calif.--(business wire)---- $eq--equillium, inc. (nasdaq: eq), a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders with high unmet medical need, today announced that three abstracts were accepted for presentation at acr convergence, the annual meeting of the american college of rheumatology. the meeting, the world's premier virtual rheumatology experience, will take place online november 3 - 10. title: itolizumab, a novel anti-cd6
EQ Ratings Summary
EQ Quant Ranking